
A FAVOURABLE DIASTEREOSELECTIVE SYNTHESIS OF N-(1-S-ETHOXYCARBONYL-3-PHENYLPROPYL)-S-ALANINE

H. Urbach * and R. Henning

Hoechst AG, Pharma Synthese, 6230 Frankfurt/Main 80


Summary: N-(1-S-Ethoxycarbonyl-3-phenylpropyl)-S-alanine is prepared by Michael addition of S-alaninebenzylester to ethyl-4-oxo-4-phenyl-2-butenoate in a regio- and diastereoselective fashion and subsequent catalytic hydrogenolysis.

N-(1-S-Ethoxycarbonyl-3-phenylpropyl)-S-alanine <u>1</u> is a portion of the molecule of the angiotensin-converting-enzyme (ACE)-inhibitors Hoe 498 $\underline{2}^{1)}$, MK 421 $\underline{3}^{2}$, CI 906 $\underline{4}^{3)}$ and others, which have attracted great therapeutic interest in the cardiovascular field.



In view of studying structure-activity relationships of ACE-inhibitors we looked for a favourable synthesis of 1. Treatment of trans-ethyl-4-oxo-4-phenyl-2-butenoate 5^{4} with S-alaninebenzyl-ester <u>6</u> in ethanol at room temperature in the presence of $N(C_2H_5)_3$ gives rise to a diastereomeric mixture of <u>7</u> and <u>8</u> exclusively in a Michael type addition in 97 % yield (Scheme I).


Scheme I



The diastereomer $\underline{7}$ with (S,S)-configuration is only slightly soluble in ethanol and precipitates out of solution in 55 - 65 % yield (mp: 73 - 74 ${}^{\circ}C, [\kappa]_{D}^{20}$: -17.8° (c = 1, CH₃OH)). After cooling of the mother liquor another portion of $\underline{7}$ precipitates out (total yield 77 %). $\underline{7}$ is subjected to catalytic hydrogenolysis (Pd/C, H₂, glacial acetic acid containing 1.6 % conc. H₂SO₄ (v/v), 25 - 30 ${}^{\circ}C$, 1 atm) to give $\underline{1}$ in 91 % yield (mp: 148 - 150 ${}^{\circ}C, [\kappa]_{D}^{20}$: + 28,2° (c = 1, CH₃OH)). The (R,S)-diastereomer $\underline{8}$, which has to be used immediately after filtration of $\underline{7}^{50}$, is hydrogenated in the same manner to give $\underline{9}$ in 74 % yield (mp: 128 - 130 ${}^{\circ}C, [\kappa]_{D}^{20}$: = -25° (c = 1, CH₃OH)).

To confirm the configuration of $\underline{1}$ and $\underline{9}$ we carried out the following reaction sequence (Scheme II):

Scheme II



The racemic triflate <u>10</u> (rac. hydroxyester, $(CF_3SO_2)_2O$, pyridine, CH_2Cl_2 , $O^{\circ}C$, 84 % yield) reacts with S-alaninebenzylester and $N(C_2H_5)_3$ in CH_2Cl_2 at room temperature to give the diastereomeric mixture of <u>11</u> and <u>12</u>, which can be separated easily by column chromatography (SiO₂, cyclohexane/diisopropylether 8 : 2). <u>11</u> is eluted as the less polar compound ($[\mathcal{L}]_D^{2O}$: -0.4° (c = 1, CH_3OH); <u>12:</u> $[\mathcal{L}]_D^{2O}$: -11.4° (c = 1, CH_3OH)). <u>11</u> and <u>12</u> were debenzylated (Pd/C/H₂, C_2H_5OH , r. t., 1 atm) to give <u>9</u> (mp: 136 - 137 °C; $[\mathcal{L}]_D^{2O}$: -27,9° (c = 1, CH_3OH)) and <u>1</u> (mp: 148 - 149 °C, $[\mathcal{L}]_D^{2O}$: +28,0° (c = 1, CH_3OH)). To decide whether <u>1</u> or <u>9</u> possessthe (S,S)-configuration, the triflate <u>10</u> (R-config.)⁶) was subjected to the reaction with S-alaninebenzylester <u>6</u>. Under inversion <u>12</u> was obtained exclusively⁸ which was debenzylated to give <u>1</u>, which has the (S,S)-configuration. Accordingly, <u>9</u> possesses the (R,S)-configuration.

Acknowledgement: We are grateful to Dr. H.-W. Fehlhaber for analytical support

References and Notes:

1) P.U. Witte, M. Metzger, R. Irmisch, <u>Naunyn-Schmiedeberg's Arch. Pharmacol.</u> <u>324</u> (Suppl.): R 75 (1983). R.H.A. Becker, B.A. Schoelkens, Th. Unger, W. Linz, <u>Naunyn-Schmiedeberg's</u> <u>Arch. Pharmacol.</u> <u>324</u> (Suppl.): R 42 (1983).

- 2) Drugs Fut. 8, 731 (1983).
- 3) Pharmacologist 24, Abs. 446 (1982).
- 4) G. P. Rice, J. Amer. Chem. Soc. 45, 233 (1923).
- 5) <u>7</u> is the thermodynamically more stable product in comparison to <u>8</u>. <u>8</u> (oil) is converted into crystalline (<u>7</u>) after standing at room temperature for several days. ¹H-NMR (270 MHz) of <u>8</u> (CDCl₃) : <u>6</u> = 1.23 (t, 3H); 1.32 (d, 3H); 3.37 (m, 2H); 3,54 (q, 1H); 3.91 (t, 1H); 4.13 (m, 2H); 5.13 (m, 2H); 7.25 - 8.0 (m, 10H) ppm ¹H-NMR (270 MHz) of <u>7</u> (CDCl₃): <u>6</u> = 1.23 (t, 3H); 1.35 (d, 3H); 3.43 (m, 2H); 3.65 (q, 1H); 3.81 (t, 1H); 4.18 (q, 2H); 5.14 (m, **2**H); 7.25 - 7.95 (m, **1**0H) ppm.
- 6) <u>10</u> (R-config.) is obtained by the following reaction:

$$\underbrace{\bigcirc}_{CH_2CH_2-CH-CO_2H} \overset{7)}{\underset{OH}{\overset{13}{\overset{}}}} + C_{2H_5OH} \overset{HCl_{gas}}{\underset{H}{\overset{}}} \underbrace{\bigcirc}_{CH_2CH_2-CH-CO_2C_{2H_5}} \overset{Hcl_{gas}}{\underset{OH}{\overset{}}}$$

 $[\alpha]_D^{20}$: -22.1° (c = 1, CHCl₃) bp: 96 - 98 °C/_{0.04}

 $\frac{(CF_3SO_2)_2O/Pyr}{CH_2Cl_2, r. t.} \xrightarrow{10; 10 \text{ was used as a crude product}}$

(tl c: one spot; SiO₂, cyclohexane/ethylacetate 9 : 1, R_f: 0.36).

- 7) D. Biquard, Ann. de Chimie 20, 146 (1933).
- F. Effenberger could show that triflates of optically pure *<*-hydroxycarboxylic esters react with amines under inversion to yield the corresponding amine derivatives⁹.
- F. Effenberger, U. Burkhard, J. Willfahrt, <u>Angew. Chem.</u> <u>95</u>, 50 (1983). (Received in Cermany 5 January 1984)